Page 17 - Lupin

Stocks to Watch: RIL, ITC, TCS, Titan, Cadila, Emami, Lupin, EIH, Tyre

BoI, Devyani Intl, Eveready, FSL, Mahindra Life, Paytm, REC, Siemens, Sintex, SPARC, Tata Steel, Thermax and Vijaya Diagnostics are some of the prominent companies to announce results today.

Sensex snaps 3-day winning run, ends 770 pts down; Nifty tops 17,750

Among sectors, all the key indices ended in the red, led by the Nifty IT index (down 2 per cent) and the Nifty Realty index (down 1.7 per cent). Nifty Auto index was the only gainer, up 0.4 per cent.

Stocks to Watch: HP Adhesives, RBL Bank, Adani Trans, HUL, Lupin, CBI

HP Adhesives is likely to debut with a 20-25 per cent listing gain, as per indications from the GMP

Lupin receives tentative USFDA nod for generic Azilsartan Medoxomil tablets

The tentative approval by the US Food and Drug Administration (USFDA) for the abbreviated new drug application (ANDA) Azilsartan Medoxomil tablets is for strengths of 40 mg and 80 mg

US business rebound key to further upsides in Lupin, VAI may offer relief

Clearance for Goa unit is positive; near-term triggers are new launches and market share gains

Stocks to Watch: ITC, Lupin, ABFRL, Glenmark, NBFCs, Tata group stocks

The RBI on Tuesday introduced a prompt corrective action (PCA) framework for large non-banking financial companies (NBFCs)

US FDA clears Lupin's Goa plant, paves way for new product approvals

Goa plant has an annual capacity of 6 billion units of tablets, capsules or oral suspension drugs. It accounts for 18-20% of firm's US revenue

Market wrap: Benchmarks end lower for a second day; Sensex slips 166 pts

NBFCs to come under the ambit of PCA framework from Oct 2022; Anand Rathi Wealth debuts at 9% premium; WPI-based inflation hits 12-year high of 14.2% in Nov

Lupin receives inspection report from USFDA for Goa manufacturing facility

Homegrown pharma major Lupin Ltd on Tuesday said it has received the Establishment Inspection Report (EIR) from USFDA for its Goa manufacturing facility after an inspection in Sept 2021

Lupin surges 10% on good volumes after getting EIR from USFDA for Goa plant

Despite of today's gain, the stock has underperformed the market by falling 18 per cent in past six months, as compared to 10.5 per cent rally in the S&P BSE Sensex

Stocks to Watch: RIL, Lupin, SBI, Maruti, PowerGrid, Minda, BoM, Vedanta

Maruti Suzuki India (MSI) is currently analysing customer feedback to ascertain if the Jimny brand can be introduced in India

Lupin recalls 4,113 cartons of oral contraceptive medicine in US market

Homegrown drug maker Lupin is recalling 4,113 cartons of generic oral contraceptive tablets in the US, the world's largest market for medicines, due to manufacturing issues. As per the latest enforcement report issued by the US Food and Drug Administration (USFDA), Lupin's US-based unit is recalling 4,113 cartons of Tydemy (drospirenone, ethinyl estradiol & levomefolate calcium tablets, 3 mg/0.03 mg/0.451 mg and levomefolate calcium tablets, 0.451 mg). The affected lot has been produced at the company's Pithampur-based manufacturing facility in Madhya Pradesh and distributed in the US by Baltimore-based Lupin Pharmaceuticals, Inc. The company is recalling the lot due to it being Subpotent Drug, the US health regulator noted in the report. Lupin initiated the nationwide recall on November 19 this year, it added. The USFDA has classified both the recalls as class III. As per the US health regulator, a class III recall is initiated in a situation in which use of, or exposure to, a .

Lupin to set up 100 diagnostic labs and 1,000 collection centres in 5 yrs

Announced foray into fragmented diagnostic business where organised chains have less than 20% share of overall business

Pharma major Lupin announces launch of its diagnostics business

Homegrown pharma major Lupin Ltd on Friday announced the launch of its diagnostics arm as part of its strategy to provide integrated healthcare in India.

Drug maker Lupin inks pact to distribute, market Pegfilgrastim in Brazil

The company has entered into an exclusive distribution and marketing agreement with Biomm SA in Brazil

Drug firm Lupin launches generic Fenofibrate capsules in United States

Lupin on Wednesday said it has launched the capsules

Stocks to Watch: IRCTC, Airtel, SBI Cards, DLF, Tata Power, Lupin, Escorts

IRCTC and Bharti Airtel could be in focus owing to negative news flow, apart from the stocks that are likely to react to corporate earnings

Drug maker Lupin reports consolidated net loss of Rs 2,098 cr in Q2

Drug maker Lupin on Thursday reported a consolidated net loss

Q2 preview: Non-Covid revenues to hint at normalisation for healthcare cos

Companies may, however, report sequential drop in numbers as Q1FY22 coincided with outbreak of second Covid wave, say brokerages

Lupin recalls 2 hypertension drugs in US due to potential impurity

Drug firm Lupin on Thursday said its US-based arm is voluntarily recalling all batches of two hypertension drugs due to potential presence of a substance that could cause cancer. The company in a statement said that Lupin Pharmaceuticals Inc is voluntarily recalling lrbesartan tablets and lrbesartan and Hydrochlorothiazide tablets to the consumer level. The tablets have been recalled due to potential presence of N-nitrosoirbesartan impurity, a substance that could cause cancer. "As part of Lupin's ongoing assessment, analysis revealed that certain tested API batches (but not finished product batches) were above the specification limit for the impurity, N-nitrosoirbesartan," it added. Although the company has received no reports of illness that appear to relate to this issue, out of an abundance of caution it is recalling all batches of lrbesartan tablets USP 75mg, 150mg and 300mg and lrbesartan and Hydrochlorothiazide tablets USP, 150mg/12.Smg and 300mg/12.5mg in the US, Lupin ...